Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (244)	3/11/2002 5:24:13 AM
From: nigel bates	Respond to of 625

The CAT PR (are they flogging a dead horse on this one ?) - MELBOURN, England, March 11 /PRNewswire-FirstCall/ -- On 24 December 2001 Cambridge Antibody Technology (Nasdaq: CATG - news; LSE: CAT) (``CAT'') announced that the Judge in the District Court of Washington DC had issued a ruling that he intended to rule that MorphoSys does not infringe the Griffiths patent (US 5,885,793), unless persuaded that there is a genuine issue as to any material fact which would require the matter to be retried before a jury. The Judge has now confirmed that ruling principally because of the way the MorphoSys library is ``derived.'' The Judge stated in his written opinion that the dispute should be brought to a close in order that ``the parties may have the appellate review that is so clearly indicated in this case''. CAT will appeal to the Federal Circuit. The appeal process is expected to take about a year. Dr. David Chiswell, CEO at CAT, said ``CAT disagrees with the Court's interpretation of the ''derived from`` issue and is confident that there are strong grounds for Appeal. In addition to the Griffiths patent CAT is asserting a number of other patents against MorphoSys in court actions in Europe and the USA.'' ...